%20--%3e%3c!DOCTYPE%20svg%20PUBLIC%20'-//W3C//DTD%20SVG%201.1//EN'%20'http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd'%20[%20%3c!ENTITY%20st0%20'fill:%23267E9A;'%3e%3c!ENTITY%20st1%20'fill:%2378C9DA;'%3e%3c!ENTITY%20st2%20'fill:%23FFFFFF;'%3e%3c!ENTITY%20st3%20'fill:%23085580;'%3e%3c!ENTITY%20st4%20'fill:%2386C34A;'%3e%3c!ENTITY%20st5%20'fill:%232FBBCC;'%3e%3c!ENTITY%20st6%20'fill:%234C6F90;'%3e%3c!ENTITY%20st7%20'fill:%23194670;'%3e%3c!ENTITY%20st8%20'fill:%2307557E;'%3e%3c!ENTITY%20st9%20'fill:%23516E89;'%3e%20]%3e%3csvg%20version='1.1'%20id='Layer_1'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20viewBox='0%200%2032%2032'%20style='enable-background:new%200%200%2032%2032;'%20xml:space='preserve'%3e%3cg%3e%3cg%3e%3crect%20x='10.3'%20y='14'%20style='&st5;'%20width='5'%20height='4.4'/%3e%3crect%20x='10.3'%20y='12'%20style='&st5;'%20width='11.4'%20height='1'/%3e%3crect%20x='16.4'%20y='14'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='16.4'%20y='15.8'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='16.4'%20y='17.5'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='16.4'%20y='19.3'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='10.3'%20y='19.3'%20style='&st5;'%20width='5'%20height='0.9'/%3e%3cg%3e%3cpath%20style='&st5;'%20d='M22.6,22.3H9.4c-0.6,0-1.2-0.5-1.2-1.2v-10c0-0.6,0.5-1.2,1.2-1.2h13.1c0.6,0,1.2,0.5,1.2,1.2v10%20C23.7,21.7,23.2,22.3,22.6,22.3z%20M9.4,10.8c-0.1,0-0.3,0.1-0.3,0.3v10c0,0.1,0.1,0.3,0.3,0.3h13.1c0.1,0,0.3-0.1,0.3-0.3v-10%20c0-0.1-0.1-0.3-0.3-0.3H9.4z'/%3e%3c/g%3e%3c/g%3e%3cpath%20style='&st5;'%20d='M16,30.2C8.2,30.2,1.8,23.8,1.8,16S8.2,1.8,16,1.8S30.2,8.2,30.2,16S23.8,30.2,16,30.2z%20M16,2.8%20C8.7,2.8,2.8,8.7,2.8,16S8.7,29.2,16,29.2S29.2,23.3,29.2,16S23.3,2.8,16,2.8z'/%3e%3c/g%3e%3c/svg%3e)
Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Breaking News
10/30/2026
BreakingClinical TrialMyopiaRegulation
US FDA Advisory Panel Meets to Review Sydnexis’ Rejected Myopia Drop, Hear Public Comments
The US FDA Dermatologic and Ophthalmic Drugs Advisory Committee held a meeting and open public hearing on Oct. 30 in Silver Spring, Maryland, to review the new drug application (NDA) for Sydnexis’ ...
10/30/2026
BreakingCataractDealsIndiaRetinaSurgical
Appasamy Acquires Ruck and its Qube Pro Dual-Function Platform
India’s Appasamy Associates, a portfolio company of Warburg Pincus, reported Oct. 22 that it had acquired German company Ruck, manufacturer of ophthalmic surgical products for both the front and ba...
10/30/2026
BreakingCornealDry EyeGlaucomaIOLLaserPremiumPresbyopiaRetinaRevenue
Q3-2026 Ophthalmic Revenue Roundup for Bausch + Lomb, Glaukos, Novartis, Lumibird, and Lenz
Bausch + Lomb reported Oct. 28 that its Q3-2026 revenue totaled $1.4 billion, a 7 percent increase (+8 percent cc) from $1.3 billion in Q3-2025. Ophthalmic pharmaceuticals segment revenue was $367 ...
10/30/2026
BreakingClinical TrialGene TherapyRegulationRetina
US FDA Gives Green Light to Trial of Opus’ Gene Therapy for RDH12-LCA
Opus Genetics announced on Oct. 21 that the US FDA had signed off on its investigational new drug application, allowing the company to proceed with a clinical trial of OPGx-RDH12, a gene therapy ca...
10/30/2026
BreakingDry EyeStudy
Researchers Develop New Standardized Grading System for MGD
A study published Oct. 6 in Clinical Optometry introduces the Meibomian Gland Composite Score (MGCS)—a standardized grading system that could help clinicians more precisely track meibomian gland dy...
10/30/2026
BreakingDiagnosticLaserRetina
Volk Launches ClearField Pro Lens for Retinal Exams, Laser Treatment
Volk Optical announced Oct. 7 the launch of ClearField Pro, a new ophthalmic lens designed for retinal examination and laser indirect ophthalmoscopy. The lens’ advanced coating provides up to 77 pe...
10/30/2026
BreakingDealsOcular CancerOcular Surface
Visara Gains Exclusive Option to Acquire Candidate for Ocular Surface Squamous Neoplasia
Visara, the ophthalmology subsidiary of NovaBridge Biosciences, announced Oct. 20 that it had gained an exclusive option to acquire worldwide rights to YOLO Immune’s YOL104-2, a candidate for ocula...
10/30/2026
BreakingDiagnosticDigitalGlaucomaPerimetry
RadiusXR, Topcon Introduce InspirePro Wearable Perimeter
RadiusXR and strategic partner Topcon Healthcare introduced the lightweight, wearable InspirePro perimeter at the American Academy of Ophthalmology’s 2026 meeting, held Oct. 10-12 in New Orleans, L...
10/30/2026
BreakingCornealDry EyeRegulation
Stuart Submits IND Amendment to US FDA for Trial of ST-100 in Corneal Wound Healing
Stuart Therapeutics announced Oct. 9 that it had submitted an investigational new drug application (IND) amendment to the US FDA to study its lead candidate, ST-100 (vezocolmitide) eye drops, in co...
10/30/2026
BreakingCell TherapyEuropeRegulationRetina
EMA Grants Orphan Drug Status to BlueRock’s IRD Cell Therapy Candidate
Bayer subsidiary BlueRock Therapeutics announced Sept. 30 that its investigational cell therapy, lemiretprocel (OpCT-001), had received orphan drug designation from the European Medicines Agency. T...
10/23/2026
BreakingDealsRetina
Alcon Acquires Neurotech and its MacTel Treatment Encelto for $550 Million
Alcon announced Oct. 20 that it had acquired Neurotech Pharmaceuticals, maker of Encelto for macular telangiectasia Type 2 (MacTel), for $550 million. Alcon said that it might be required to make a...
10/23/2026
BreakingCataractIOLPharmaPremiumRetinaRevenueSurgical
Q3-2026 Ophthalmic Revenue Roundup for Roche and J&J Vision
Swiss company Roche reported Oct. 22 that Q3-2026 Vabysmo sales were CHF 1.1 billion ($1.4 billion, converted for Sept. 20, 2026) a 13 percent increase over CHF 996 million in Q3-2025. US Vabysmo s...
10/23/2026
BreakingPharmaRegulation
US FDA Approves Alcon’s Brytly 12-Hour Redness Reliever Eye Drops
Alcon announced Oct. 16 that the US FDA had approved Brytly (apraclonidine 0.125%), a redness relieving eye drop. The company said one drop of Brytly works in one minute and lasts up to 12 hours, o...
10/23/2026
BreakingPharmaPresbyopia
US FDA Approves Ryzumvi from Opus and Viatris for Presbyopia
Commercial partners Viatris and Opus Genetics reported Oct. 16 that the US FDA had approved Ryzumvi (phentolamine ophthalmic solution 0.75%) as a treatment for presbyopia. The milestone marks the f...
10/23/2026
BreakingClinical TrialIndustryPharmaRetina
EyePoint to Slash Workforce, End Pivotal Wet AMD Trials After Second Miss for Duravyu
EyePoint announced Oct. 19 that it would cut its workforce by 53 percent and end the Phase III trials for Duravyu in wet age-related macular degeneration (AMD) early after the LUCIA study failed to...
10/23/2026
BreakingPharmaRegulationRetina
Belite Files for Approval of Oral Stargardt Candidate in Singapore, UK, Switzerland
Belite Bio announced Oct. 14 that it had filed for marketing approval for its oral Stargardt treatment candidate, tinlarebant, in three countries—Singapore, the UK, and Switzerland—under those nati...
10/23/2026
BreakingDiagnosticPerimetry
Haag-Streit and Marco Lombart Launch Octopus 910 Perimeter in the US
Haag-Streit USA and distributor Marco Lombart reported Oct. 10 that they had launched the Octopus 910 perimeter in the US. A global launch is set for January 2027. The full-field projection perimet...
9/4/2026
BreakingCataractEuropeGlaucomaIndiaIndustryMeetingNewsletterRefractiveRetina
2026-2027 Ophthalmic Meetings Calendar
Market Scope regularly updates its list of ophthalmic meetings to keep the information current. Please contact us at matthewdouty@market-scope.com if we do not have your meeting listed. Thank you.
10/16/2026
BreakingRegulationThyroid Eye Disease
US FDA Approves Genentech’s Enspryng, the First Subcutaneous Treatment for TED
Genentech and its parent, Roche, announced Oct. 16 that the US FDA had approved Enspryng (satralizumab-mwge) for the treatment of adults with thyroid eye disease (TED). It’s the first at-home, subc...
10/16/2026
BiosimilarsBreakingEuropeRegulationRetina
Alvotech, Advanz Submit Marketing Application to EMA for High-Dose Aflibercept Biosimilar
Alvotech and partner Advanz Pharma announced Oct. 14 that they had submitted a marketing authorization application to the European Medicines Agency (EMA) for AVT29, a proposed biosimilar to Eylea (...
10/16/2026
BreakingClinical TrialPharmaRetina
Merck Sees Mixed Results at One Year in Pivotal Trial of Remigromig in DME
Merck presented one-year results from remigromig’s pivotal Phase IIb/III BRUNELLO trial at the 2026 meeting of the American Academy of Ophthalmology (AAO), held Oct. 10-12 in New Orleans, Louisiana...
10/16/2026
BreakingIndustryPharmaSurgical
Saunders Departs Bausch + Lomb, as Chairman Appio Takes Over
Bausch + Lomb announced Oct. 12 that CEO Brent Saunders would leave the company immediately, with chairman Thomas Appio taking over as interim CEO. Appio also is CEO of Bausch Health. Saunders had ...
10/16/2026
BreakingPharmaRegulationRetinaUveitis
US FDA Accepts BLA for Genentech’s Vamikibart in UME; Decision Expected by July 2027
Genentech, a member of the Roche group, reported Oct. 10 that the US FDA had accepted the biologics license application (BLA) for vamikibart, an intravitreal IL-6 inhibitor candidate for uveitic ma...
10/16/2026
BreakingCornealDeals
Visara Licenses Topical Neurotrophic Keratitis Candidate from China’s Hiteck
Visara, the ophthalmic subsidiary of NovaBridge Biosciences, announced Oct. 13 that it had licensed a topical candidate targeting neurotrophic keratitis (NK) from China’s Wuhan Hiteck Biopharma. VI...
10/16/2026
BreakingInstrumentsSingle-UseSurgical
Corza Medical Launches Expanded Single-Use Custom Packs
Corza Medical, of Boulder, Colorado, announced Oct. 10 the launch of its expanded Blink single-use custom surgical packs. The company also debuted a new automated manufacturing process for its Shar...
10/16/2026
BreakingCataractSurgical
HelpMeSee Names Former Test Pilot Doug May as President and CEO
Global nonprofit group HelpMeSee announced Oct. 1 that it had appointed Doug May as president and chief executive officer. May joined HelpMeSee in 2025 as chief operating officer. He previously wor...
10/9/2026
BreakingDealsRetina
Glaukos Licenses Tri-specific Retinal Candidate RO-104 from RevOpsis
Glaukos announced Oct. 8 that it had licensed from RevOpsis Therapeutics the exclusive rights to develop and commercialize RO-104, a novel tri-specific biologic candidate targeting wet age-related ...
10/9/2026
BreakingCataractDealsDiagnosticGlaucomaIOLPerimetryPremium
Carrot, Maker of VR Visual Field Testing, Acquires IOL Simulation Developer GreenMan
Carrot (formerly Virtual Field) reported Oct. 9 that it had agreed to acquire GreenMan Vision, of West Fargo, North Dakota, and its InSightVR IOL simulator. No financial details were provided. The ...
10/9/2026
BreakingDiagnosticRetina
Sagent Launches Zyogreen Ready-to-Use Indocyanine Green Dye for Injection in the US
Sagent Pharmaceuticals, of Schaumburg, Illinois, announced Sept. 22 the US launch of Zyogreen (indocyanine green injection). Sagent said Zyogreen is the first and only FDA-approved ready-to-use ind...
10/9/2026
BreakingGlaucomaStudy
Study Indicates that Circadian Rhythm and Light May Affect IOP
Researchers at the University of South Florida (USF) reported Sept. 30 that continuously monitoring intraocular pressure (IOP) in a rat model showed that eye pressure follows a daily rhythm, consis...
10/9/2026
BreakingGene TherapyRetina
Nobel Prize for Medicine Goes to Team First to Publish Optogenetics Findings
Three scientists who helped develop optogenetics received the 2026 Nobel Prize in Physiology or Medicine on Oct. 5. They are Karl Deisseroth, MD, PhD, of the Howard Hughes Medical Institute in Mary...
10/9/2026
BreakingDealsDiagnostic
VEO Ophthalmics to Market the VitaPixel Visualization System for Slit Lamps
VEO Ophthalmics and VitaPixel announced a collaboration Oct. 2 under which VEO will market the VitaPixel SVS, a stereoscopic digital visualization system for slit lamps. The VitaPixel SVS combines ...
10/9/2026
BreakingGene TherapyRegulationRetina
Japanese Regulators Accept NDA for Nanoscope’s Optogenetic Gene Therapy Candidate, Grant Priority Review
Nanoscope Therapeutics announced Oct. 1 that regulators in Japan had accepted the company’s new drug application for Mogenry, an optogenetic gene therapy candidate targeting inherited retinal dystr...
10/9/2026
BreakingClinical TrialPharmaRegulationRetina
US FDA Gives Green Light to Trial of Surrozen’s DME Candidate
Surrozen announced on Oct. 2 that the US FDA had signed off on its investigational new drug application, allowing the company to proceed with a clinical trial of SZN-8141, a bifunctional Wnt agonis...
10/2/2026
BreakingDealsGlaucomaIOL
SpyGlass Acquires IOL Maker Advanced Vision Science for $13 Million
SpyGlass Pharma announced Oct. 1 that it had acquired all outstanding shares of common stock in Advanced Vision Science (AVS), a manufacturer of intraocular lenses and lens materials, for $13 milli...
10/2/2026
BreakingDealsOptometry
MyEyeDr. Acquires Optometry Division of EyeCare Partners
MyEyeDr., of Vienna, Virginia, announced Sept. 28 that it would acquire the optometry division of EyeCare Partners, of St. Louis, Missouri. The deal covers the optometric brands of Clarkson Eyecare...
10/2/2026
BreakingDry EyePharmaRegulation
Aldeyra to File Formal Dispute with US FDA over Reproxalap Rejection
Aldeyra Therapeutics reported Sept. 29 that it would submit a formal dispute resolution request with the US FDA over the rejection of reproxalap, a topical treatment candidate for dry eye disease. ...
10/2/2026
BreakingGene TherapyRegulationRetina
Ocugen Gains Provisional Approval in Bahamas to Treat RP Patients with OCU400
Ocugen announced Sept. 25 that OCU400, its subretinal modifier gene therapy candidate targeting retinitis pigmentosa (RP), had been granted provisional approval and priority designation by regulato...
10/2/2026
BreakingCataractIndustryRefractiveRetinaSurgical
Sightpath Medical Adds Retinal Equipment to Mobile Offering
Sightpath Medical reported Sept. 22 that it now delivers retinal equipment for ophthalmic surgery. The company’s mobile services for retina specialists include delivery of a vitrectomy platform in ...
10/2/2026
BreakingCell TherapyChinaClinical TrialRetina
iRegene’s RP Cell Therapy Candidate Gets Green Light for Clinical Trials in China, US
China’s iRegene Therapeutics announced Sept. 29 that its cell therapy candidate targeting retinitis pigmentosa (RP) gained authorization from regulators to enter clinical trials in both China and t...
10/2/2026
BreakingCataractIOLPremiumSurgical
InSightVR IOL Simulator Linked to Increased Premium Lens Selection, Better Understanding
GreenMan Vision, of West Fargo, North Dakota, reported Sept. 21 that its InSightVR IOL simulator was associated with several key benefits in a study published Sept. 5 in the journal Patient Prefere...
10/2/2026
BreakingCornealIndustryPharma
Claris Bio Establishes Corporate Headquarters in San Francisco
Claris Bio reported Sept. 24 that it had moved its corporate headquarters from Jersey City, New Jersey, to San Francisco, California. Its new home is at 701 Gateway Blvd., Suite 250, South San Fran...
9/25/2026
BreakingDealsMyopiaRegulation
FDA Panel Meeting for Sydnexis’ Rejected Myopia Drop Candidate Set for Oct. 30
Sydnexis reported Sept. 24 that the US FDA had set Oct. 30 as the date for an advisory committee and open public hearing to review the new drug application (NDA) for SYD-101, an atropine eye drop c...
9/25/2026
BreakingCataractIOLRegulationSurgical
Rayner Launches RayOne Galaxy IOL in US after Receiving FDA Approval
UK-based Rayner announced Sept. 24 that its RayOne Galaxy and RayOne Galaxy Toric IOLs were commercially available in the US after the lenses gained FDA approval. The company noted that US surgeons...
9/25/2026
BreakingEuropeRegulationRetina
Roche Gains EU Approval for Susvimo Sustained-Release Wet AMD Treatment
Swiss drugmaker Roche announced Sept. 21 that the European Commission had granted marketing authorization for Susvimo (ranibizumab injection) 100 mg/mL for the treatment of wet age-related macular ...
9/25/2026
BreakingDiagnosticFundusOCTRetina
Zeiss Introduces Alta Duo 300, a Fully Automated OCT Combination Retinal Imager
Zeiss Medical Technology reported Sept. 17 that it had introduced the Alta Duo 300 combination retinal imager. The device will be available in select markets later in 2026. The German company said ...
9/25/2026
BreakingDiagnosticFundusOCTRetina
Combination OCT-Fundus Camera Headlines Product Launches from Nidek
Japan’s Nidek announced Sept. 3 the launch of three new ophthalmic diagnostic offerings. The RSD-1 Duo, a combined OCT and fundus camera system, and the AFC-1 fundus camera increase efficiency acro...
9/25/2026
AllergyBreakingDry EyeRegulation
UK Pet Food Company Concludes Recall After Reports of Sudden Dry Eye Symptoms in Dogs
The Years pet food company, based in the UK, has concluded a recall of all its fresh pet food products after an independent investigation found no link between its ingredients and dog owners’ repor...
9/25/2026
BreakingPharmaRegulation
Bausch + Lomb Receives FDA Warning Letter for Tampa, Florida, Plant, Citing Persistent Contamination
The US FDA sent Bausch + Lomb a warning letter Sept. 4 regarding significant violations observed at its manufacturing plant in Tampa, Florida, during an FDA inspection in March 2026. The Tampa loca...
9/25/2026
BreakingFundingRetinaStudy
€1 Million Champalimaud Vision Award in 2026 Goes to Botond Roska and José-Alain Sahel
The winners of the 2026 António Champalimaud Vision Award are researchers Botond Roska, MD, PhD, of Switzerland, and José-Alain Sahel, MD, of France and the US, for their pioneering optogenetic the...
9/25/2026
BreakingIndustryLaserRetina
Norlase Establishes Direct Commercial Presence in the United Kingdom
Norlase announced on Sept. 8 that it had expanded its footprint in Europe with a direct commercial presence in the United Kingdom. The Danish company, with US offices in Redwood City, California, a...
9/25/2026
BreakingChinaMyopiaRegulation
Chinese Regulators Accept NDA for Low-Dose Atropine Drop for Myopia from Santen
Japan’s Santen announced Sept. 14 that China’s National Medical Products Administration (NMPA) had accepted the new drug application (NDA) for STN1012700 (atropine sulfate ophthalmic solution 0.025...
9/18/2026
BreakingEuropeGlaucomaLaser
Lumibird Medical Launches Astral Contactless SLT Platform with Integrated OCT
France’s Lumibird Medical announced Sept. 12 the launch of the Astral, a contactless selective laser trabeculoplasty (SLT) platform for glaucoma. The device was unveiled at the 2026 congress of the...
9/18/2026
BreakingDeviceGlaucomaRegulation
Balance Ophthalmics Announces 2026 Medicare Pricing for FSYX Pump and Goggles
Balance Ophthalmics reported Aug. 18 that regulators had set 2026 Medicare payment amounts for the FSYX Ocular Pressure Adjusting Pump (OPAP) and associated goggles, effective Oct. 1. The FSYX pump...
9/18/2026
BreakingClinical TrialDeviceGlaucomaRegulationSurgical
US FDA Gives Green Light to Trial of Ciliatech’s Intercil Uveal Spacer for Glaucoma
France’s Ciliatech announced Sept. 8 that the US FDA had signed off on its investigational device exemption (IDE) submission, allowing the company to proceed with a feasibility study of its Interci...
9/18/2026
BreakingGene TherapyRegulationRetina
US FDA Accepts BLA for Nanoscope’s Optogenetic Gene Therapy Candidate in RP
Nanoscope Therapeutics announced Sept. 9 that the US FDA had accepted for review its biologics license application (BLA) for Mogenry, an optogenetic gene therapy candidate designed to restore visio...
9/18/2026
BreakingPharmaRegulationRetina
Surrozen Submits IND Application for Dual-Acting SZN-8141 in DME
Surrozen announced Sept. 8 that it had submitted an investigational new drug (IND) application to the US FDA to launch a clinical trial of SZN-8141, a bifunctional Wnt agonist and vascular endothel...
9/18/2026
BreakingChinaDealsGlaucomaPharmaRegulation
Chinese Regulators Accept NDA for Glaucoma Drop from Nicox, Ocumension
France’s Nicox and partner Ocumension Therapeutics, of China, announced Sept. 11 that China’s National Medical Products Administration (NMPA) had accepted the new drug application (NDA) for NCX 470...
9/18/2026
BreakingPharmaRegulationRetina
Belite Bio Submits NDA in Japan for Oral Tinlarebant in Stargardt
Belite Bio announced Sept. 8 that it had submitted a new drug application (NDA) for its oral Stargardt treatment candidate, tinlarebant, to Japan’s Ministry of Health, Labour, and Welfare. Tinlareb...
9/18/2026
BreakingFundingRetina
Foundation Fighting Blindness Renames Venture Arm as Gund Vision Fund
The Foundation Fighting Blindness, of Columbia, Maryland, reported Sept. 10 that it had renamed its venture philanthropy arm the Gund Vision Fund. The fund was formerly called the Retinal Degenerat...
9/11/2026
BreakingCataractCornealRefractive
Bausch + Lomb Gains CE Marking for SeeLyra Femtosecond Laser
Bausch + Lomb reported Sept. 11 that its SeeLyra next-generation femtosecond laser had gained CE marking. The company said the SeeLyra, built on the Victus platform, is designed to provides surgeon...
9/11/2026
BreakingCataractIOLMeeting
Rayner Launches Galaxy Hydrophobic Spiral IOL
UK-based Rayner reported Sept. 7 the launch of its Galaxy Hydrophobic spiral IOL at the 2026 ESCRS congress in London. The lens will be available commercially in the EU in Q4-2026. The original Gal...
9/11/2026
BreakingCataractEuropeIOLMeeting
Zeiss Announces Launch of AT Lucia Toric 721P
Zeiss Medical Technology reported Sept. 10 that it was launching its AT Lucia Toric 721P IOL at the 2026 ESCRS congress in London. Zeiss, of Germany, described the lens as the world's first hyd...
9/11/2026
BreakingEuropeRetinaSingle-Use
Oxford Eye Hospital Initiative Cuts IVT Injection Waste and Costs
Britain’s Oxford Eye Hospital reported Aug. 24 that an initiative there to change the way intravitreal (IVT) injections are administered has eliminated tons of associated single-use product waste a...
9/11/2026
BreakingCataractEuropeIOL
Alcon’s Clareon Monofocal Lens Gains MDR Certification, Expanded Labeling
Alcon reported Sept. 1 that it had gained MDR certification in the European Union for its Clareon Monofocal enhanced monofocal intraocular lens. The company noted that the hydrophobic acrylic lens ...
9/11/2026
BreakingRetina
British Company Exonate Rebrands as Foventa Therapeutics
British company Exonate announced Sept. 1 that it had changed its name to Foventa Therapeutics. The company said its new name and motto “Simply Sharper” take inspiration from the fovea, the center ...
9/11/2026
BreakingClinical TrialCorneal
European Consortium Studies Gene-Silencing Eye Drops Targeting Corneal Vascularization
Two studies underway at the University of Cologne in Germany will test whether a new class of eye drops silencing the insulin-receptor substrate 1 (IRS1) gene can slow the blood vessel growth that ...
9/11/2026
BreakingCornealEurope
Stem Cell Treatment Improves Vision for Aniridia-Related Keratopathy
Researchers at Moorfields Eye Hospital and the University College of London have developed a collagen scaffold that delivers limbal epithelial and stromal stem cells to improve vision in eyes with ...
9/11/2026
BreakingGlaucoma
University of Virginia Team Uses Nanotechnology to ID New Target for Treating Glaucoma
Researchers at the University of Virginia have used cutting-edge nanotechnology to probe Schlemm’s canal and identify a potential new genetic target to regulate aqueous humor drainage in patients w...
9/4/2026
BreakingDiagnosticMicroscopesSurgical
Alcon Launches Unity M Ophthalmic Surgical Microscope
Alcon announced Sept. 3 the initial commercial launch of its Unity M ophthalmic surgical microscope. The company said the microscope, which has received CE marking in Europe and regulatory approval...
9/4/2026
BreakingCornealMyopiaRefractive
X-Cel and Essilor Launch Lunara Orthokeratology Lens
X-Cel Specialty Contacts and Essilor Custom Contacts announced Aug. 31 the US launch of Lunara, a new FDA-approved orthokeratology lens. Orthokeratology, or ortho-k, uses specially designed and fit...
9/4/2026
AIBreakingDiagnosticSurgical
AI Replaces Presurgical Scans in Removal of Sight-Threatening Brain Tumor
The European Medical Journal reported Aug. 28 that artificial intelligence had provided real-time guidance for removal of a vision-threatening brain tumor at University College London Hospital (UCL...
9/4/2026
BreakingCataractGlaucomaIOLIndustryPharmaSurgical
SpyGlass Celebrates Grand Opening of New Irvine, California, Headquarters
SpyGlass Pharma celebrated the grand opening of its new Irvine, California, headquarters on Aug. 27, as the company continues to expand. SpyGlass was initially founded in Irvine in 2019 by Malik Y....
9/4/2026
BreakingDiagnosticDry Eye
Ophthalmologist Urges Early Intervention in Dry Eye Management to Avoid Surprises
Jason Bacharach, MD, of North Bay Eye Associates in northern California, has a word of advice for ophthalmologists and optometrists. Four words, actually: interventional dry eye management (IDEM). ...
9/4/2026
Breaking
Basketball Topped US Sports Eye Injuries Treated in 2025, Statistics Show
Basketball had the highest rate of sports-related eye injuries treated in the US in 2025, with 5,236 injuries, according to new statistics published Aug. 26 by Prevent Blindness. The Chicago, Illin...
9/4/2026
AIBreakingDeviceDiagnosticRegulation
US FDA Asks for Feedback on GenAI Medical Device Regulation
The US FDA took inspiration from the way human clinicians are trained in drafting a proposal for the regulation of medical devices that feature generative artificial intelligence (GenAI), and it’s ...
9/4/2026
BreakingDealsRetina
Kiora Licenses Retinal Candidate to Chong Kun Dang for South Korea
Kiora Pharmaceuticals announced Aug. 10 that it had granted Chong Kun Dang (CKD) Pharmaceutical Corp. development and commercialization rights in South Korea to KIO-301 for the treatment of degener...
9/4/2026
BreakingIndustryLow VisionRetina
Samsara Vision Promotes Jason Herod to President and Chief Executive Officer
Samsara Vision, of Far Hills, New Jersey, announced Sept. 1 that Jason Herod had been promoted to president and chief executive officer. Herod joined Samsara in 2021 and most recently served as chi...
8/28/2026
BreakingCataractEquipmentEuropeSurgical
Zeiss Introduces Cataract-Only Version of DORC Eva Nexus
German company Carl Zeiss Meditec introduced on Aug. 27 a dedicated cataract version of the DORC Eva Nexus surgical system. The original Eva Nexus, a dual-function cataract and vitrectomy machine, ...
8/28/2026
BreakingDealsGlaucomaPharmaRegulation
US FDA Accepts NDA for Glaucoma Drop from Nicox and Kowa, Sets PDUFA Date of April 30, 2027
France’s Nicox announced Aug. 27 that the US FDA had accepted the new drug application (NDA) for NCX 470 (bimatoprost grenod; also known as K-911) and set a Prescription Drug User Fee Act (PDUFA) t...
8/28/2026
BreakingClinical TrialDry EyePharma
Bausch + Lomb Advancing Dual-Action Dry Eye Drop, Ocular Surface Pain Candidate
Bausch + Lomb reported Aug. 24 that it would advance two of its topical ocular pipeline candidates based on clinical trial results. The company’s dual-action dry eye drop candidate—combining lifite...
8/28/2026
BreakingMyopiaStudy
Indigo Light Prevents Myopia Completely in Animal Model, Researchers Find
Vision researchers have found that indigo light prevents myopia completely in a tree shrew model. Their findings were published Aug. 18, 2026, in Cell Reports Medicine. The study’s lead researchers...
8/28/2026
BreakingRegulation
Light-Filtering Lenses for Migraine from Avulux Gain US FDA De Novo Marketing Nod
Avulux announced Aug. 24 that its eyeglass lenses had gained US FDA de novo marketing authorization to decrease the impact of light sensitivity in patients ages 12 and older diagnosed with episodic...
8/28/2026
BreakingGlaucomaPharma
Santen Launches Rhopressa Glaucoma Drops in Japan
Santen announced Aug. 17 that it had launched Rhopressa (netarsudil ophthalmic solution) 0.02%, an eye drop targeting glaucoma and ocular hypertension, in Japan. The treatment gained marketing appr...
8/28/2026
BreakingPharmaRegulationRetina
Japan Grants Orphan Status to Alkeus’ Oral Gildeuretinol for Stargardt
Alkeus Pharmaceuticals announced Aug. 24 that Japan’s Ministry of Health, Labour, and Welfare had granted orphan drug status to gildeuretinol, its oral therapy candidate for Stargardt disease. In J...
8/21/2026
BreakingCataractChinaFLACSGlaucomaLaserPresbyopiaRefractiveRetinaRevenueSurgical
Q2-2026 Ophthalmic Revenue Roundup for STAAR, Lensar, Iridex, and Lenz
STAAR Surgical, of Lake Forest, California, reported Aug. 12 that its Q2-2026 net sales were $93.5 million, a 111 percent increase over $44.3 million in Q2-2025. China sales in Q2-2026 were $52.3 m...
8/21/2026
BreakingDealsEuropePresbyopia
Lupin’s Visufarma Licenses Yuvezzi Presbyopia Drops for Europe, UK
Visufarma, a subsidiary of India-based Lupin Limited, announced Aug. 20 that it had licensed exclusive rights to the presbyopia drop Yuvezzi in the European Union, the UK, Switzerland, Norway, and ...
8/21/2026
BreakingDeviceDry EyeRegulation
TearCare Label Expanded to Include Improvement of Meibomian Gland Function
Sight Sciences reported Aug. 19 that the US FDA had expanded the labeling for the TearCare thermal expression device to include improvement of meibomian gland function in adult patients with evapor...
8/21/2026
BiosimilarsBreakingDiagnosticIOLPharmaRetinaRevenueSurgical
Quarterly Revenue Roundup for Carl Zeiss Meditec and Santen
German company Carl Zeiss Meditec reported Aug. 6 that its ophthalmic device revenue for the three months ended June 2026 (the third quarter of its fiscal 2025/2026 year) was €437.6 million ($499.7...
8/21/2026
BreakingClinical TrialRetina
EyePoint’s Duravyu Misses Primary Visual Acuity Endpoint in Phase III Wet AMD Trial
EyePoint Pharmaceuticals reported Aug. 17 that Duravyu (vorolanib intravitreal insert) missed its primary visual acuity endpoint in topline results from the Phase III LUGANO trial in wet age-relate...
8/21/2026
BreakingDiagnosticDigital
Zeiss Gains US FDA 510(k) Clearance for Clinic 360 Data Management Software
Carl Zeiss Meditec announced Aug. 19 that it had gained 510(k) clearance from the US FDA for its Clinic 360 image and data management software. The clinical analytics dashboard combines diagnostic ...
8/21/2026
BreakingCell TherapyStudy
Researchers Aim to Conquer Jet Lag Using Engineered RPE Cells
Researchers at Rice and Northwestern universities have developed a subcutaneous therapy using engineered retinal pigment epithelial (RPE) cells that they say could help the body adapt more quickly ...
8/14/2026
BreakingPharmaRegulationRetina
US FDA Accepts NDA for Belite’s Oral Stargardt Candidate, Grants Priority Review
Belite Bio announced Aug. 11 that the US FDA had accepted its new drug application (NDA) for its oral Stargardt treatment candidate, tinlarebant. The agency granted priority review, and set a Presc...
8/14/2026
BreakingCataractDry EyeGlaucomaIOLOcular CancerPharmaRetinaRevenueSurgical
Q2-2026 Ophthalmic Revenue Roundup for Alcon, Tarsus, Immunocore, Harrow, Sight Sciences, and ANI
Alcon reported Aug. 10 that its Q2-2026 net sales totaled $2.8 billion, an 8 percent increase over $2.6 billion in Q2-2025. Alcon also announced that it had discontinued work on the PowerVision Flu...
8/14/2026
BreakingDealsRetina
Oculis Buys Out Global Rights to Privosegtor from Accure
Swiss company Oculis announced Aug. 10 that it would obtain worldwide development and commercialization rights to privosegtor as part of an asset purchase agreement with Spain’s Accure Therapeutics...
8/14/2026
BreakingDealsDry EyeEurope
Italy’s Alfasigma to Acquire Nordic Pharma, Maker of Lacrifill Canalicular Gel
Italian pharmaceutical company Alfasigma announced Aug. 11 that it would acquire 100 percent of the shares of Nordic Group BV (Nordic Pharma) and its subsidiaries from Sever Life Sciences. Financia...
8/14/2026
BreakingChinaDealsGlaucomaPharmaRegulation
Nicox Partner Ocumension Submits NDA in China for Glaucoma Drop
France’s Nicox announced Aug. 10 that its partner Ocumension Therapeutics, of China, had submitted a new drug application (NDA) to China’s National Medical Products Administration for NCX 470, a ni...
8/14/2026
BreakingChinaClinical TrialRetina
US FDA Gives Green Light to Trial of Ractigen’s saRNA Candidate in PVR
China’s Ractigen Therapeutics reported on July 31 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase I clinical trial of ...
8/14/2026
BreakingGene TherapyRegulationRetina
US FDA Grants RMAT Status to Ocugen’s Gene Therapy Candidate for GA
Ocugen announced July 29 that the US FDA had granted regenerative medicine advanced therapy (RMAT) designation to OCU410, the company’s subretinal gene therapy candidate for geographic atrophy (GA)...
8/7/2026
BreakingDealsDry EyePharmaRetina
Tarsus to Acquire Alkeus Pharmaceuticals in Deal Worth up to $800 Million
Tarsus Pharmaceuticals, maker of Xdemvy, announced Aug. 6 that it would acquire Alkeus Pharmaceuticals in a cash-and-stock deal worth up to $800 million. Under the deal, Tarsus will pay $450 milli...
8/7/2026
BiosimilarsBreakingCataractIOLLaserPharmaRetinaRevenueSurgicalThyroid Eye Disease
Q2-2026 Ophthalmic Revenue Roundup for Regeneron, Amgen, Hoya, Astellas, Novartis, Lumibird, Ocular Therapeutix, and Xbrane
Regeneron, of Tarrytown, New York, reported July 30 that its Q2-2026 US revenue for Eylea HD and Eylea 2 mg was $1.0 billion, a 12 percent decrease from $1.15 billion in Q2-2025. Eylea HD accounted...
8/7/2026
BiosimilarsBreakingRetina
Biocon Launches Eylea Biosimilar Yesafili in the US
India’s Biocon Limited announced on Aug. 3 the commercial launch of Yesafili (aflibercept-jbvf), a biosimilar to Eylea 2 mg, in the US. Yesafili was among a flurry of Eylea biosimilars approved by ...
8/7/2026
BreakingDealsDry EyePharma
Harrow Acquires Global Rights to Tyrvaya Nasal Spray for Dry Eye
Harrow, of Nashville, Tennessee, announced Aug. 6 that it would acquire global rights to Tyrvaya (varenicline) nasal spray for dry eye from Viatris. Under the deal, Harrow will pay $30 million up f...
8/7/2026
BreakingDeviceGlaucomaMIGSRegulation
Sight Sciences Gains US FDA 510(k) Clearance for Omni Ultra Glaucoma Device
Sight Sciences announced Aug. 4 that it had gained 510(k) clearance from the US FDA for the Omni Ultra surgical system. Sight Sciences, of Menlo Park, California, said the Ultra is indicated for ca...
8/7/2026
BreakingDiagnosticEuropeFundusRegulation
Topcon Gains CE Marking for Gaia Ultra-widefield Retinal Imager
Topcon Healthcare announced July 17 that it had gained CE marking in Europe for its Gaia ultra-widefield retinal imaging device. Topcon says Gaia offers true-color fundus imaging, with a 209-degree...
8/7/2026
BreakingIndiaIndustryRetinaSurgical
Aravind, Alcon Open Centre of Excellence for Vitreoretinal Surgery Training in India
Aravind Eye Care System and Alcon reported July 24 that they had launched the Aravind Alcon Global Centre of Excellence for Vitreoretinal Surgery Training in Coimbatore, India. The move marks the s...
8/7/2026
BreakingIndustryRefractiveSurgical
STAAR Surgical Appoints Warren Foust as President and Chief Executive Officer
STAAR Surgical, of Lake Forest, California, reported Aug. 4 that it had appointed Warren Foust as president and chief executive officer. Foust and Deborah Andrews, STAAR’s chief financial officer, ...
8/7/2026
BreakingEuropePharmaRegulationRetina
Roche Receives Positive CHMP Opinion for Susvimo Sustained-Release Wet AMD Treatment
Swiss drugmaker Roche announced July 24 that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had recommended marketing authorization in the European Union for ...
8/7/2026
BreakingFundingGlaucomaPharmaRegulation
Nicox Partner Kowa Submits NDA to US FDA for Glaucoma Drop
France’s Nicox announced July 1 that its partner Kowa, of Japan, had submitted a new drug application to the US FDA for NCX 470, also known as K-911, a nitric oxide-donating bimatoprost eye drop ca...
7/31/2026
BreakingPharmaRegulationRetina
US FDA Approves Outlook’s Lytenava (Bevacizumab) for Wet AMD
Outlook Therapeutics announced July 24 that it had gained US FDA approval for Lytenava (bevacizumab-vikg) to treat wet age-related macular degeneration (AMD). The news comes after years of regulato...
7/31/2026
BreakingGlaucomaRegulationSurgical
Glaukos Changes US Regulatory Pathway for PreserFlo, Completes Enrollment in 510(k) Study
Glaukos reported July 27 that it had completed patient enrollment in a 510(k) pivotal study for the PreserFlo MicroShunt. The glaucoma drainage device is implanted ab externally to increase outflow...
7/31/2026
BreakingCataractCornealDry EyeGene TherapyGlaucomaIOLMIGSPharmaRetinaRevenueSurgical
Q2-2026 Ophthalmic Revenue Roundup for Bausch + Lomb, Roche, and Glaukos
Bausch + Lomb reported July 29 that its Q2-2026 revenue was $1.4 billion, a 9 percent increase over $1.3 billion in Q2-2025, driven by a 64 percent increase in implantables, including a 175 percent...
7/31/2026
BreakingEuropeLow VisionRetina
Science Corp. Launches Prima Retinal Implant in Europe
Science Corporation reported July 22 that it had launched its Prima retinal implant in Europe for patients with geographic atrophy (GA) caused by age-related macular degeneration (AMD). The company...
7/31/2026
BreakingCataractIOLPremiumSurgical
Bausch + Lomb Launches EyeGility Preloaded IOL Inserter in the US
Bausch + Lomb announced July 16 that it had launched the EyeGility Inserter preloaded IOL (intraocular lens) delivery system in the US. The inserter is available now with the enVista Aspire interme...
7/31/2026
BreakingDealsPresbyopiaRegulation
Marketing Application Submitted in Australia for Orasis’ Presbyopia Drop
Orasis Pharmaceuticals announced July 15 that its partner Aspen Australia had submitted a new drug application to Australia’s Therapeutic Goods Administration for Orasis’ pilocarpine hydrochloride ...
7/31/2026
AllergyBreakingDeals
Santen and Kyorin to Jointly Market Eyelid Cream for Allergic Conjunctivitis in Japan
Japanese pharmaceutical companies Santen and Kyorin announced July 13 that they would jointly market Santen’s Alesion long-acting eyelid cream (epinastine hydrochloride 0.5%) for allergic conjuncti...
7/31/2026
BreakingGene TherapyRegulationRetina
Atsena’s Gene Therapy Candidates for XLRS, LCA1 Gain EMA Orphan Designation
Atsena Therapeutics announced July 23 that the European Medicines Agency (EMA) had granted orphan designation to its two clinical-stage gene therapy candidates: ATSN-101 for Leber congenital amauro...
7/24/2026
BreakingCataractGlaucomaRegulationRetinaSurgical
CMS Proposes Cuts to Physician Fees for 2027; Simple Cataract Surgery Would Pay $462 or $444
The Centers for Medicare and Medicaid Services (CMS) on July 14 published its proposed Physician Fee Schedule (PFS) for 2027. Similar to the 2026 schedule, one of two conversion factors will be use...
7/24/2026
BreakingCataractDealsDry EyeGlaucomaLaserRetina
IPG Photonics to Acquire Lumibird Medical for €300 Million
IPG Photonics has entered into a binding offer to acquire Lumibird Medical for €300 million (US $342.3 million), both companies announced July 16. A contingent earnout consideration of up to an add...
7/24/2026
AIBreakingPharmaRegulation
Kalshi Offers Betting on Drug Development Timelines and Results
Prediction market Kalshi began on July 16 offering betting on a range of drug development milestones, ranging from clinical trial outcomes and timelines for submissions to US FDA decisions. The New...
7/24/2026
BreakingGene TherapyRetina
Atsena Will Advance ATSN-401 Gene Therapy Candidate for Stargardt
Atsena Therapeutics announced July 9 that it would advance ATSN-401, a gene therapy candidate for Stargardt disease. Stargardt is an inherited neurodegenerative disease that leads to macular degene...
7/24/2026
BreakingDealsGene TherapyRetina
Ocugen Secures Deal with Roots Pharmaceutical for OCU400 in MENA Region
Ocugen announced July 13 that it had signed a binding term sheet for a license agreement with Kuwait’s Roots Pharmaceutical for exclusive rights to OCU400, Ocugen’s subretinal modifier gene therapy...
7/24/2026
BreakingMyopiaRegulation
Santen Gains Philippines Marketing Approval for Ryjusea (Atropine) for Myopia
Japan’s Santen Pharmaceutical announced June 26 that it had gained marketing approval in the Philippines for preservative-free Ryjusea low-dose atropine drops to slow the progression of pediatric m...
7/24/2026
BreakingCornealRegulation
US FDA Grants RMAT Status to Emmecell’s Corneal Cell Therapy Candidate
Emmecell announced July 7 that the US FDA had granted regenerative medicine advanced therapy (RMAT) designation to EO2002, the company’s corneal endothelial cell therapy candidate. The RMAT designa...
7/24/2026
BreakingIndustryPharmaRetina
NovaBridge Biosciences Appoints Srishti Gupta, MD, as Chief Executive Officer
NovaBridge Biosciences announced June 29 that it had appointed Srishti Gupta, MD, as chief executive officer and a member of the company’s board of directors. The company said that Xi-Yong (Sean) F...
7/24/2026
BreakingIndustryPharmaRetina
Exonate Appoints Olav Hellebø as Chief Executive Officer
British company Exonate announced June 30 that it had appointed Olav Hellebø as chief executive officer. Exonate is developing EXN407, an eye drop candidate entering Phase IIb study for diabetic ey...
7/17/2026
BreakingMyopiaRegulation
US FDA Advisory Panel Will Review Sydnexis’ NDA for SYD-101 in Myopia
Sydnexis announced July 13 that the US FDA would convene an advisory committee meeting to discuss SYD-101, the company’s low-dose atropine candidate for pediatric progressive myopia. The date for t...
7/17/2026
AllergyBreakingCataractPharmaRegulationRetina
US FDA Recalls 2.5 Million Bottles of Prednisolone Acetate Eye Drops
The US FDA has issued a Class II recall of more than 2.5 million bottles of prednisolone acetate 1% eye drops manufactured by Lupin Limited, citing the possibility of foreign particulate contaminat...
7/17/2026
BreakingClinical TrialGlaucomaRetina
Bausch + Lomb Drops Glaucoma Neuroprotection Program after Phase II Failure
Bausch + Lomb announced July 10 that it would discontinue development of a neuroprotective eye drop candidate for glaucoma, citing Phase II results in which BL1107, a prodrug of brimonidine tartrat...
7/17/2026
BreakingCataractIOLIndustrySurgical
RxSight Appoints Aziz Mottiwala as President, CEO
RxSight reported July 15 that it had appointedAziz Mottiwala as president and chief executive officer, effective July 20. Mottiwala succeeds Ron Kurtz, MD, who will continue to serve as chief medic...
7/17/2026
BreakingCataractIOLPremiumRevenueSurgical
J&J Vision Generates Q2-2026 Surgical Revenue of $426 Million
J&J Vision’s Q2-2026 global surgical revenue totaled $426 million, a 5.6 percent increase over $403 million in Q2-2025, parent Johnson & Johnson, of New Brunswick, New Jersey, reported July 15. Q2-...
7/17/2026
BreakingDealsDry EyeRetinaSurgical
Tarsus Acquires iRenix, Developer of Pre-procedure Ocular Antiseptic Candidate
Tarsus Pharmaceuticals announced July 8 that it had acquired iRenix Medical, of Palo Alto, California, developer of IRX-101, an investigational ocular antiseptic. Tarsus said it would pay approxima...
7/17/2026
BreakingPresbyopiaRegulation
Tenpoint Submits UK Marketing Application for Yuvezzi Presbyopia Drops
Tenpoint Therapeutics reported July 13 that it had submitted a marketing authorization application to the UK’s Medicines and Healthcare Products Regulatory Agency for Yuvezzi (carbachol and brimoni...
7/17/2026
BreakingChinaDry EyeRegulation
Hengrui’s Cyclosporine Eye Drop Formulation for Dry Eye Gains Approval in China
China’s Hengrui Pharmaceuticals and Germany’s Novaliq announced June 30 that China’s National Medical Products Administration had approved Heng Yi (0.1% cyclosporine ophthalmic solution) for dry ey...
7/17/2026
BreakingDealsLow Vision
Vivani’s Cortigent to Merge with Nasdaq-Listed ClearOne
Vivani Medical, of Alameda, California, reported July 2 that its Cortigent subsidiary— which is developing the Orion visual cortex implant—would merge with Nasdaq-listed ClearOne to form Cortigent ...
7/10/2026
BreakingCataractDealsIOLPremiumPresbyopiaSurgical
Alcon and RxSight to Collaborate on Developing Adjustable PC-IOLs
Alcon and RxSight willjointly develop adjustable presbyopia-correcting intraocular lenses (PC-IOLs) under a new nonexclusive agreement, the companies announced July 6. The collaboration aims to com...
7/10/2026
BiosimilarsBreakingRetina
Harrow Relaunches Lucentis Biosimilar Byooviz in the US
Harrow announced July 1 that it had relaunched Byooviz (ranibizumab-nuna), a Lucentis biosimilar, in the US. The Nashville, Tennessee, company secured US rights to Byooviz and another ophthalmic bi...
7/10/2026
BreakingCataractDiagnosticFLACSIndustryRefractiveSurgical
LensCrafters Adds Refractive and Cataract Surgery Options to New Center
LensCrafters, part of French company EssilorLuxottica, announced June 30 that it was launching the first LensCrafters Vision & Eye Health Center, addingsurgical procedures and advanced diagnostics ...
7/10/2026
BreakingRegulationThyroid Eye Disease
US FDA Accepts sBLA for Genentech Subcutaneous TED Candidate, Grants Priority Review
Genentech announced June 30 that the US FDA had accepted its supplemental biologics license application (sBLA) for subcutaneous Enspryng (satralizumab) in thyroid eye disease (TED). The agency gran...
7/10/2026
BreakingCataractIOLPremiumStudySurgical
Global Team of Ophthalmologists Creates Questionnaire for Reporting Dysphotopsias
Twenty multinational ophthalmic specialists, including key opinion leaders, have developed a consensus-based classification system and questionnaire for reporting dysphotopsias after ophthalmic pro...
7/10/2026
AIBreakingCataractDigitalSurgical
Bausch + Lomb Rolls Out Orphia Digital Platform, Initially Focused on Patient Education
Bausch + Lomb reported July 9 the introduction of Orphia, a new AI-powered digital health platform intended to increase eye care providers’ efficiency. It will initially provide pre-surgery catarac...
7/10/2026
BreakingDry EyeStudy
Researchers Develop Dry Eye Candidate Powered by Spinach and Light
Researchers in Singapore have developed a spinach-derived nanotechnology that enables corneal cells to produce a key antioxidant molecule when exposed to ambient light. The team at the National Uni...
7/10/2026
BreakingCataractIndiaSurgical
HelpMeSee Accelerates MSICS Training in India with New Center in Guwahati
Global nonprofit group HelpMeSee and its Indian subsidiary, HMS Vision Private Limited, have launched virtual training for manual small incision cataract surgery (MSICS) in Guwahati, India. Trainin...
7/10/2026
BreakingCell TherapyGene TherapyIndustry
New Marketplace Aims to Rescue Shelved Cell and Gene Therapies
Hundreds of cell and gene therapy (CGT) candidates have been shelved in recent years—not because they failed patients, but because they weren’t considered commercially viable. A new joint venture a...
7/2/2026
BreakingGlaucomaPharmaRegulationSurgical
MACs Propose Limiting Coverage for iDose TR
Five Medicare administrative contractors (MACs) in the US are proposing to limit coverage for procedures implanting the Glaukos iDose TR in patients with glaucoma. The iDose TR is a drug-eluting in...
7/2/2026
BreakingRegulationThyroid Eye Disease
Viridian Announces US FDA Approval and Launch of Lumvoa for Thyroid Eye Disease
Viridian Therapeutics announced June 29 that the US FDA had approved Lumvoa (veligrotug-vvze), an infusion treatment for thyroid eye disease (TED). The Waltham, Massachusetts, company said it would...
7/2/2026
BreakingDealsPresbyopia
Lenz Licenses Vizz Presbyopia Drops to Arrotex for Australia, New Zealand
Lenz Therapeutics announced June 24 that it had granted Arrotex Pharmaceuticals exclusive rights to develop Vizz (aceclidine ophthalmic solution) 1.44% eye drops for presbyopia in Australia and New...
7/2/2026
BreakingDealsIndustryRetina
LambdaVision Collaborates with Vast, Creator of Planned Commercial Space Station
LambdaVision reported June 24 that it had signed a memorandum of understanding with Vast related to future research and manufacturing activities for LambdaVision’s artificial retina aboard Vast’s p...
7/2/2026
BreakingPharmaRegulation
Supreme Court Ruling in Favor of Bayer May Shut Down Thousands of Roundup Lawsuits
German company Bayer won a landmark ruling in the US Supreme Court on June 25, when justices ruled 7-2 that federal pesticide laws preempt “failure-to-warn” claims made under state law. The plainti...
7/2/2026
BreakingDiagnosticFundus
Optos Celebrates Milestone of 30 Thousand Installed Imaging Devices
UK-based Optos reported June 25 that it had reached the milestone of 30 thousand imaging devices installed globally. The company developed and continues to be a leader in single-capture, 200-degree...
7/2/2026
BreakingCataractDiagnosticGlaucomaMicroscopesRetinaSurgical
BVI Opens Experience Hub for Ophthalmic Training, Collaboration
BVI Medical, of Waltham, Massachusetts, announced June 15 that it had opened a new BVI Experience Hub within its offices in Sant Cugat, Spain. The hub is designed to support ophthalmic training and...
7/2/2026
BreakingLow Vision
Braille Institute Names Six Recipients of Community Hero Awards
The Braille Institute of America honored six recipients of its Community Hero Awards at a dinner on June 25. The awards recognize extraordinary organizations and leaders for breaking barriers, expa...
6/26/2026
BreakingCornealLaserOptometryScope of Practice
Vermont Expands ODs’ Scope to Include SLT, LPI, YAG Capsulotomy, Crosslinking
Vermont has become the 17th US state to pass a law expanding optometrists’ scope of practice to include in-office laser procedures. Senate Bill 64, signed into law by Gov. Phil Scott on June 18, gr...
6/26/2026
BreakingGlaucomaPharma
Théa Pharma Launches Zolymbus Bimatoprost Gel for Glaucoma in the US
Théa Pharma, the Massachusetts-based subsidiary of France-based Théa, announced June 15 that it had launched Zolymbus (bimatoprost ophthalmic gel) 0.01% in the US. Thepreservative-free formulation ...
6/26/2026
BreakingDeviceGlaucomaSurgical
Hexiris Showcases Glaucoma Devices Targeting Office-Based Surgery
Canada’s Hexiris Ophthalmics reports that it is showcasing at ophthalmic meetings its glaucoma device candidates targeting office-based surgery, with an eye toward a commercial launch in 2026. Surg...
6/26/2026
BreakingCataractDealsPharma
Formosa Licenses Clobetasol Drops to Samil for Vietnam
Taiwan-based Formosa Pharmaceuticals announced June 11 that it had expanded its licensing agreement with Samil Pharmaceuticals for clobetasol propionate 0.05% eye drops for postsurgical inflammatio...
6/26/2026
BreakingDry EyeRetina
Scope Health Adds Vision Support and Eye Comfort Eyetamins to its Optase Product Line
Scope Health, of New York, announced June 17 that it had added Eyetamins Vision Support and Eye Comfort versions to its Optase line of eyelid hygiene and ocular lubricant products. The Eye Comfort ...
6/26/2026
BreakingDry EyePharma
Ocusoft Introduces Retaine Ultra PF Preservative-Free Artificial Tears
Ocusoft, of Rosenberg, Texas, announced on June 17 the launch of Retaine Ultra PF, a lubricating eye drop available in a preservative-free multi-dose bottle. Its active ingredients include polyethy...
6/26/2026
BreakingGlaucomaIndustryPharma
Essential Pharma Appoints Becki Morison as Chief Executive Officer
UK-based Essential Pharma announced June 18 that it had appointed Becki Morison as chief executive officer, effective July 1. Morison succeeds Simon Ball, who has served as interim CEO since Novemb...
6/19/2026
BreakingChinaDealsRefractiveSurgical
Aier Eye Hospital Group to Buy 25 VisuMax 800 Lasers from Zeiss
German company Carl Zeiss Meditec reported June 17 that the Aier Eye Hospital Group in China had agreed to buy 25 VisuMax 800 femtosecond lasers for its hospital locations starting this year. The V...
6/19/2026
BreakingIndustry
Johnson & Johnson to Invest $1 Billion in Jacksonville, Home of J&J Vision
Johnson & Johnson reported June 15 that it would invest more than $1 billion in its Jacksonville, Florida, operations to scale US-based manufacturing, packaging, and distribution capabilities for i...
6/19/2026
BreakingPharmaRegulationRetina
Belite Bio Completes Rolling NDA Submission for Oral Tinlarebant in Stargardt
Belite Bio announced June 12 that it had completed its rolling new drug application (NDA) submission to the US FDA for oral tinlarebant for the treatment of Stargardt disease. The San Diego, Califo...
6/19/2026
BreakingCataractIOLSurgical
J&J Expands US Rollout of Tecnis PureSee IOL
Johnson & Johnson reported June 11 that it was expanding availability for the Tecnis PureSee IOL in the US. The lens gained US FDA approval in March 2026. The PureSee is a purely refractive extende...
6/19/2026
BreakingCataractEquipmentSurgical
Alcon Launches Unity CS Phaco System in Canada
Alcon announced June 15 the launch in Canada of the Unity CS phacoemulsification system for cataract surgery. Alcon said it planned to showcase the platform at the Canadian Ophthalmological Society...
6/19/2026
BreakingGlaucomaIndustryPharmaRetina
Tavo Biotherapeutics Appoints Federico Grossi, MD, PhD, as CMO
Tavo Biotherapeutics, of Laguna Beach, California, announced June 2 that it had appointed Federico Grossi, MD, PhD, as chief medical officer (CMO). Grossi most recently was CMO of Unity Biotechnolo...
6/19/2026
BreakingCornealDry EyeRegulation
TearSolutions Gains Orphan, Fast Track Status for Lacripep in Neurotrophic Keratitis
TearSolutions announced June 2 that the US FDA had granted orphan drug and fast track designations for its synthetic peptide eye drop candidate Lacripep in neurotrophic keratitis (NK). NK is a rare...
6/12/2026
BreakingChinaDealsPresbyopia
Everest Acquires Rights in Greater China to Lenz’ Vizz for Presbyopia
Everest Medicines, of Shanghai, China, has acquired rights in Greater China to Lenz Therapeutics’ Vizz (LNZ100) eye drops for presbyopia, Lenz reported June 7. Lenz, of San Diego, California, said ...
6/12/2026
BiosimilarsBreakingEuropeRetina
Formycon’s Aflibercept Biosimilar in Prefilled Syringes Now Available in EU
Germany’s Formycon announced May 19 that its aflibercept (Eylea) biosimilar, known in various territories as Ahzantive and Baiama, was now available in the European Union. It is being introduced in...
6/12/2026
BiosimilarsBreakingEuropeRetina
Samsung Bioepis Launches Aflibercept Biosimilar Branded Opuviz in EU
Korea’s Samsung Bioepis announced May 29 that it had launched Opuviz, a biosimiliar referencing Eylea (aflibercept), across Europe. The biosimilar is also available in Korea and Canada as Aflivu. H...
6/12/2026
AllergyBreakingDry EyePharma
Harrow Relaunches Verkazia in the US for Vernal Keratoconjunctivitis
Harrow reported June 10 that it had relaunched Verkazia (cyclosporine ophthalmic emulsion, 0.1%) in the US for the treatment of vernal keratoconjunctivitis (VKC). VKC is a serious allergic eye dise...
6/12/2026
AIBreakingDealsDigital
AAO Licenses Clinical Practice Guidelines to OpenEvidence Chatbot for Doctors
The American Academy of Ophthalmology reported June 9 that it had licensed the guidance in itsPreferred Practice Patterns and Ophthalmic Technology Assessments to OpenEvidence for its medical AI pl...
6/12/2026
BreakingCataractPharmaRegulation
Apotex Gains Health Canada Approval for Iheezo Ophthalmic Anesthesia
Toronto’s Apotex announced May 26 that it had secured Health Canada marketing approval for Iheezo (chloroprocaine hydrochloride ophthalmic gel 3%), a topical anesthetic indicated for ocular surface...
6/12/2026
BreakingDry Eye
Bausch + Lomb Launches Blink Triple Care Preservative Free Drops in US
Bausch + Lomb announced June 1 the US launch of Blink Triple Care Preservative Free eye drops. The lipid- and water-based formula combines a natural oil—to help keep tears from evaporating too quic...
6/12/2026
BiosimilarsBreakingRegulationRetina
Lupin Gains US FDA Approval for Ranibizumab Biosimilar Branded Ranluspec
India’s Lupin Limited announced June 4 that the US FDA had approved Ranluspec (ranibizumab-hkdz) as an interchangeable biosimilar referencing Lucentis. Lupin said Ranluspec was the only interchange...
6/12/2026
BiosimilarsBreakingRegulationRetina
Alvotech Resubmits BLA to US FDA for Aflibercept Biosimilar
Alvotech, of Reykjavik, Iceland, reported June 4 that it had resubmitted its biologics license application (BLA) to the US FDA for AVT06, a biosimilar to Eylea (aflibercept). Alvotech said it had a...
6/12/2026
BreakingDiagnosticOCTRetina
Optos Names Alexandre Montague as CEO
UK-based Optos announced June 9 that it had appointed Alexandre Montague as chief executive officer, effective immediately. Optos, a subsidiary of Japan’s Nikon, pioneered ultra-widefield retinal i...
6/5/2026
BreakingClinical TrialPharmaRetina
Oculis Scraps DME Eye Drop Program after Phase III Failure
Swiss company Oculis reported May 29 that it would not pursue US FDA approval for OCS-01, its dexamethasone eye drop candidate targeting diabetic macular edema (DME), after the primary endpoint of ...
6/5/2026
BreakingPharmaRegulationRetina
Outlook Therapeutics Resubmits BLA for Lytenava After Winning Appeal with FDA
Outlook Therapeutics reported June 1 that it had resubmitted its biologics license application (BLA) to the US FDA for Lytenava, its ophthalmic formulation of bevacizumab for the treatment of wet a...
6/5/2026
BreakingCataractEuropeSingle-UseSurgical
Rayner Launches New Ophteis Cohesive OVD, Rebrands Line
UK-based Rayner announced June 1 the launch of Ophteis Cohesive, a new ophthalmic viscosurgical device (OVD) developed and manufactured at its biomaterials facility in Portugal. The company said th...
6/5/2026
BreakingDealsLaserRetina
Zeiss, M2care Invest in Maculaser, Developer of Temperature-Controlled Retinal Laser Therapy
Finland-based Maculaser Oy has received a new investment from Zeiss Ventures, the corporate venture capital arm of Germany’s Zeiss Group, and M2care, a European health tech venture studio, as Macul...
6/5/2026
BreakingCataractDealsRefractiveSurgical
Sightpath to Deliver IQity’s Products Through Mobile Platform Under New Partnership
Reno, Nevada-based IQity reported May 21 that it was partnering with Sightpath Medical to deliver its technology to surgeons. IQity is developing eight products expected to launch between 2027 and ...
6/5/2026
AmblyopiaBreakingDeals
Luminopia Licenses Amblyopia Therapy to Rohto for Japan Market
Luminopia, of Cambridge, Massachusetts, reported June 2 that it had licensed its pediatric amblyopia treatmentto Rohto Pharmaceutical Co. to develop and commercialize in Japan. Rohto is a Japanese ...
6/5/2026
BreakingPharmaRegulation
US FDA Leadership Shakeup Continues as Drug Division Chief Exits
The US FDA’s drug evaluation division has another new leader. Michael Davis, MD, PhD, has been named acting director of the Center for Drug Evaluation and Research (CDER), according to the FDA’s we...
6/5/2026
BreakingFundingOptometry
Georgia Southern University Gains Funding for State’s First College of Optometry
Georgia Southern University announced May 26 that it had received $29.8 million in state funding to establish the first college of optometry in Georgia. The school said the money will support the r...
5/29/2026
BreakingCataractGlaucomaIOL
SpyGlass Gains Category III CPT Code for Its Drug-Eluting BIM-IOL System
SpyGlass Pharma, of Aliso Viejo, California, reported May 18 that the American Medical Association had approved a new add-on Category III CPT code that will allow surgeons to be reimbursed separate...
5/29/2026
BreakingCataractDiagnosticIOL
Carl Zeiss Meditec Names Bronwyn Brophy O’Connor as CEO
German company Carl Zeiss Meditec reported May 22 that it had appointed Bronwyn Brophy O’Connor as chief executive officer and a member of the management board. Zeiss said O’Connor brings 25 years ...
5/29/2026
BreakingGlaucomaRefractiveRetina
Q1-2026 Ophthalmic Revenue Roundup for Apellis, Immunocore, STAAR, and Iridex
Apellis Pharmaceuticals, of Waltham, Massachusetts, reported May 7 in its quarterly financial report for Q1-2026 that its net product revenue for Syfovre was $150.7 million, a 15.4 percent increase...
5/29/2026
BreakingLaserMyopia
Myopia Management Roundup: Research Includes Study Raising Safety Concerns over Some Red-Light Devices
A laboratory study published this year in JAMA Ophthalmology calls into question the safety of commercially available red-light therapy devices as a treatment option for young myopes. Repeated low-...
5/29/2026
BreakingGlaucoma
Study Links Vitamins B3 and B12 to Lower Risk of Glaucoma
Researchers in the Netherlands recently assessed the link between B vitamin intake and glaucoma. Their findings were published in April in the American Journal of Ophthalmology. B vitamins play an ...
5/29/2026
BreakingEuropeGlaucomaLaser
ViaLase Announces First Commercial FLIGHT Procedures in Glaucoma Patients
ViaLase, of Aliso Viejo, California, announced May 26 that surgeons in London and Germany had performed the first commercial procedures using its ViaLuxe Laser System for femtosecond laser image-gu...
5/29/2026
BreakingCataractIOL
Patients Satisfied with Same-Day Bilateral Cataract Surgery, Study Finds
Danish researchers who interviewed same-day bilateral cataract surgery patients found that the patients appreciated the convenience and welcomed empathetic communication before, during, and after t...
5/29/2026
BreakingDry Eye
Video Series from World Council of Optometry and Alcon Summarizes TFOS DEWS III
The World Council of Optometry (WCO) and Alcon have released a series of three videos to help eye care professionals understand and apply recommendations from the updated Dry Eye Workshop III (DEWS...
5/29/2026
BreakingRegulationRetina
US FDA Signs Off on Special Protocol Assessment for Oculis’ Optic Neuritis Trial
Swiss company Oculis announced May 7 that the US FDA had agreed to a special protocol assessment regarding PIONEER-1, a Phase III clinical trial evaluating Privosegtor for the treatment of optic ne...
5/22/2026
BreakingCataractIOLPharma
Annual and Quarterly Ophthalmic Revenue Roundup for Santen, Carl Zeiss Meditec, Harrow, RxSight, ANI, and Lensar
Japan-based Santen reported May 12 that its revenue for its fiscal year 2025, which ended March 31, 2026, was JPY 291.6 billion ($1.8 billion, calculated for March 31, 2026), a 2.8 percent decline ...
5/22/2026
BreakingRetina
Bausch + Lomb Launches PreserVision AREDS3 Eye Vitamins in the US
Bausch + Lomb reported May 19 that it had launched its PreserVision AREDS3 eye vitamins in the US. The supplements add a unique B-vitamin complex to the AREDS2 nutrients recommended by the National...
5/22/2026
BreakingMyopia
Myopia Management Roundup: SightGlass, Hoya Tout Positive Results with Spectacle Lenses
SightGlass Vision reported May 6 that its DOT spectacle lenses for myopia control saved more than 1 diopter of progression on average after two years in a study of Chinese children ages 6 to 10. Th...
5/22/2026
BreakingGene TherapyRetina
Portuguese Study of Luxturna Shows Functional Benefits, Structural Decline
Luxturna (voretigene neparvovec) has demonstrated in clinical trials and real-world studies that it improves light sensitivity and functional vision, with a favorable safety profile. A new prospect...
5/22/2026
BreakingOptometry
AOA Honors Leaders in Optometry With 2026 Annual Awards
The American Optometric Association (AOA), the American Optometric Student Association, and the AOA Foundation have announced the recipients of the organizations’ 2026 annual awards. The winners ar...
5/15/2026
BreakingDeviceDry EyeGlaucomaPharmaPresbyopiaRevenue
Q1-2026 Ophthalmic Revenue Roundup for Tarsus, Sight Sciences, and Lenz
Tarsus Pharmaceuticals, of Irvine, California, reported May 6 that its Q1-2026 revenue for Xdemvy was $145.4 million, an 85 percent increase over $78.3 million in Q1-2025. Xdemvy (lotilaner ophthal...
5/15/2026
BreakingDevicePharmaRegulation
US FDA Commissioner Makary Resigns After Rocky Year in Top Job
US FDA Commissioner Marty Makary, MD, MPH, resigned May 12 after a rocky year in the agency’s top job that saw mass layoffs, high-level resignations, and policy fights with lawmakers, drugmakers, a...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.